偏倚作为伊维菌素治疗COVID-19试验不一致性的来源:一项系统综述。伊维菌素的 suggested 获益主要基于潜在偏倚的结果。
该系统综述检索截至2021年7月6日的L.OVE平台,纳入29项随机对照试验共5592例,比较伊维菌素与标准治疗或其他活性治疗。总体证据确定性极低至低,提示伊维菌素可能带来重要获益;但排除偏倚高风险或存在一些担忧的试验后,多数效应估计发生实质性改变,低确定性证据提示伊维菌素可能不降低死亡率(RD 每1000例减少7例)也不降低机械通气(RD 每1000例增加6例),中等确定性证据显示其可能不增加症状缓解或改善(RD 每1000例增加14例)也不增加病毒清除(RD 每1000例减少12例)。结论认为伊维菌素可能不改善COVID-19患者的临床重要结局,其作为暴露后预防干预的效果不确定,先前得出重要获益的报道基于方法学局限性显著的研究所报告的潜在偏倚结果,需进一步研究。
要点
- 纳入29项RCT共5592例,总体证据确定性极低至低。
- 排除高偏倚风险试验后,多数效应估计发生实质性改变。
- 低确定性证据提示伊维菌素可能不降低死亡率和机械通气。
核心结论
- 伊维菌素可能不改善COVID-19患者的临床重要结局,其作为暴露个体的预防干预效果不确定。
- 先前报告伊维菌素重要获益的结论基于方法学局限性显著的研究所报告的潜在偏倚结果。
- 需进一步研究。
研究设计与样本
- 系统综述,检索L.OVE平台截至2021年7月6日,纳入比较伊维菌素与标准治疗或其他活性治疗的随机对照试验(RCT)。
- 共纳入29项RCT, enrolled 5592例。
- 采用随机效应配对Meta分析,使用GRADE方法评估证据确定性,并进行排除偏倚风险试验的敏感性分析。
主要发现
- 总体证据确定性为极低至低,提示伊维菌素可能带来重要获益。
- 排除偏倚评估中分类为「高风险」或「存在一些担忧」的试验后,多数效应估计发生实质性改变。
- 与标准治疗相比,低确定性证据提示伊维菌素可能不降低死亡率(RD 每1000例减少7例)也不降低机械通气(RD 每1000例增加6例)。
- 中等确定性证据显示伊维菌素可能不增加症状缓解或改善(RD 每1000例增加14例)也不增加病毒清除(RD 每1000例减少12例)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this systematic review is to summarize the effects of ivermectin for the prevention and treatment of patients with COVID-19 and to assess inconsistencies in results from individual studies with focus on risk of bias due to methodological limitations. METHODS: We searched the L.OVE platform through July 6, 2021 and included randomized trials (RCTs) comparing ivermectin to standard or other active treatments. We conducted random-effects pairwise meta-analysis, assessed the certainty of evidence using the GRADE approach and performed sensitivity analysis excluding trials with risk of bias. RESULTS: We included 29 RCTs which enrolled 5592 cases. Overall, the certainty of the evidence was very low to low suggesting that ivermectin may result in important benefits. However, after excluding trials classified as "high risk" or "some concerns" in the risk of bias assessment, most estimates of effect changed substantially: Compared to standard of care, low certainty evidence suggests that ivermectin may not reduce mortality (RD 7 fewer per 1000) nor mechanical ventilation (RD 6 more per 1000), and moderate certainty evidence shows that it probably does not increase symptom resolution or improvement (RD 14 more per 1000) nor viral clearance (RD 12 fewer per 1000). CONCLUSION: Ivermectin may not improve clinically important outcomes in patients with COVID-19 and its effects as a prophylactic intervention in exposed individuals are uncertain. Previous reports concluding important benefits associated with ivermectin are based on potentially biased results reported by studies with substantial methodological limitations. Further research is needed.
引用
- Izcovich A, Peiris S, Ragusa M, et al. Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review. Ivermectin's suggested benefits are mainly based on potentially biased results. J Clin Epidemiol. 2021. PMID: 34933115. doi:10.1016/j.jclinepi.2021.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。